GH

Guardant Health, Inc.

18.98 USD
+0.01 (+0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Guardant Health, Inc. stock is down -13.45% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 Feb 16:40 17 Jan, 2025 15.00 CALL 60 38
23 Feb 18:08 19 Apr, 2024 22.50 CALL 250 532
23 Feb 18:23 19 Apr, 2024 20.00 PUT 208 959
23 Feb 19:05 19 Apr, 2024 22.50 CALL 449 532
23 Feb 19:31 17 Jan, 2025 30.00 CALL 399 4051
23 Feb 20:40 15 Mar, 2024 20.00 PUT 250 1136
26 Feb 18:42 17 Jan, 2025 30.00 CALL 150 3400
26 Feb 20:34 17 Jan, 2025 30.00 CALL 120 3400
28 Feb 14:39 18 Oct, 2024 20.00 PUT 75 120
28 Feb 20:53 17 Jan, 2025 30.00 CALL 497 3182

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.

  • Piper Sandler
    Mon Feb 26, 09:50
    buy
    confirm
  • JP Morgan
    Fri Feb 23, 12:37
    buy
    confirm
  • Canaccord Genuity
    Fri Feb 23, 09:41
    buy
    confirm